This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
The goal of the LOPES project (LOwer-extremity Powered ExoSkeleton) is to design and implement a gait rehabilitation robot for treadmill training. The target group consists of people who have had a stroke and have impaired motor control. The main goals of LOPES are:
The mechanical construction should offer assistance in leg movements in the forward direction and in keeping lateral balance. Within the LOPES project, it has been decided to realize this by connecting the limbs of the patient to an exoskeleton so that robot and patient move in parallel. Most gait rehabilitation robots that are currently being developed[1][2] focus on the support of the entire gait cycle as a single unit. These robots use joint trajectories of the entire gait cycle and offer a uniform (more or less) stiff control along this trajectory. This means that the patient receives support in gait phases where support is necessary but also in phases where support isn't necessary. Studies have been done on an exoskeleton [3] that propose adaptive control methods which minimize the interaction forces with the patient with respect to an adaptable reference pattern, but these still control the entire gait cycle. Studies have also shown that walking with the Lokomat requires significantly less energy than normal walking [4][full citation needed]. LOPES aims to support and not take over those tasks that the patient is unable to perform without help using an impedance control scheme. This will lead to a more active participation from the patient's side. The tradeoff for more active walking will likely be a smaller overall distance during therapy sessions. The implication of selective function support is that the robot will have two extreme modes in which it should be able to function, these are:
The first prototype has been completed. This prototype has 8 actuated DOF (series elastic actuation[5]) following the design.[6] Clinical evaluations will be done in the course of 2007.[needs update][citation needed]